Patients grouped by AD treatment
Twelve-hundred, thirty-seven patients with moderate-to-severe AD were included in the analysis (age range 9-95 years). Patients were initially grouped based on their AD treatment: 632 patients on dupilumab, 107 patients on other systemic treatments, and 498 patients on limited or no treatment. The 107 patients on other systemics included 52 on phototherapy, 29 on oral JAK inhibitors, 14 on prednisone, 6 on methotrexate, 4 on cyclosporine, and 2 on mycophenolate mofetil. Among patients on limited or no treatment, 354 were on topicals and 153 had no treatment. Demographics, medication history, and comorbidities are listed in Table 1A. No significant differences were found between groups in terms of age and race.